Drugs that contain Brexpiprazole

1. Drug name - REXULTI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7888362 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Apr, 2026

(3 years from now)

USRE48059 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders
Dec, 2028

(6 years from now)

CN101155804A OTSUKA Piperazine-Substituted Benzothiophenes For Treatment Of Mental Disorders
Apr, 2026

(3 years from now)

CN101155804B OTSUKA For Treating Mental Disease Piperazine Substituted Benzothiophene
Apr, 2026

(3 years from now)

IN251204B OTSUKA A Heterocyclic Compound Represented By The Formula(1)
Apr, 2026

(3 years from now)

IN200707041P1 OTSUKA Piperazine-Substituted Benzothiophenes For Treatment Of Mental Disorders
Apr, 2026

(3 years from now)

EP1869025B3 OTSUKA Piperazine-Substituted Benzothiophenes For Treatment Of Mental Disorders
Apr, 2026

(3 years from now)

EP1869025A1 OTSUKA Piperazine-Substituted Benzothiophenes For Treatment Of Mental Disorders
Apr, 2026

(3 years from now)

EP1869025B1 OTSUKA Piperazine-Substituted Benzothiophenes For Treatment Of Mental Disorders
Apr, 2026

(3 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8618109 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders Apr, 2026

(3 years from now)

US8349840 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders Apr, 2026

(3 years from now)

US9839637 OTSUKA Piperazine-substituted benzothiophenes for treatment of mental disorders Apr, 2026

(3 years from now)

US10307419 OTSUKA Tablet comprising 7-[4-(4-benzo[b]thiopen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or a salt thereof Oct, 2032

(10 years from now)

Treatment: Treatment of schizophrenia; treatment of schizophrenia in adults and pediatric patients ages 13 years and older; Adjunctive treatment of major depressive disorder (mdd); Adjunctive treatment of major depressive disorder (mdd); treatment of schizophrenia; treatment of schizophrenia in adults and pediatric patients ages 13 years and older

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
0.25MG TABLET;ORAL Prescription
0.5MG TABLET;ORAL Prescription
1MG TABLET;ORAL Prescription
2MG TABLET;ORAL Prescription
3MG TABLET;ORAL Prescription
4MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.